News
Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...
Penn's Kiran Musunuru spoke with The Inquirer about the future of CRISPR technology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback